cagrisema cagrilintide semaglutide phase 3 obesity drug: what the data shows Three new phase 3 REIMAGINE
Three new phase 3 REIMAGINE studies provide some of the strongest evidence yet for CagriSema (cagrilintide + semaglutide) in type 2 diabetes. REIMAGINE 1 Studied people with early type 2 diabetes Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet CagriSema for Obesity Info for Participants Phase Phase 3 Clinical Trial 2026 Power Power Cagrilintidesemaglutide (CagriSema) as an add on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double blind, placebo controlled, multicentre, phase 3 study The Lancet
Pay in 4 interest-free payments of $7.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20

01163-7/asset/66927280-fb89-41a1-ba38-d976f7426327/main.assets/gr2.jpg)
01022-6/asset/3f55ea20-b36b-4e11-88e9-940a60e8677e/main.assets/gr2_lrg.jpg)